Cancer Research Technology
Log in Register
Menu

MCF7/S0.5 Cell Line

Invented by Dr Anne Lykkesfeldt from Danish Cancer Society
Invented at Danish Cancer Society

Info

Catalogue Number 152090
Antigen/Gene or Protein Targets Oestrogen receptor
Parental Line MCF7
Host Human
Tissue Breast
Disease Keywords Breast cancer
Model Tumour line
Relevance The MCF7/S0.5 cell line has been established to grow at low serum. The presence of hormones in the serum required in tissue culture media complicates the demonstration of specific hormone and antihormone effects. Methods to overcome this have included charcoal-treated serum and serum-free medium. However, both methods have serious drawbacks. Therefore, the MCF-7/S0.5 cell line has been adapted to long-term growth at 0.5 % fetal bovine serum in order to reduce the oestrogen supply via serum and to enable oestrogen receptor-mediated growth inhibition with the antiestrogen tamoxifen.

The MCF7/S0.5 cells are also useful for studies of effect of oestrogens, if they, instead of 1 % fetal calf serum, are cultivated with 10% newborn calf serum which contains very low oestrogenic activity.
Production Details This MCF7 subline was established buy stepwise reduction in the serum concentration from 5% fetal calf serum to 0.5 % in growth medium consisting of DMEM: Ham's F-12 medium (1:1) supplemented with 2mM glutamine and insulin (6ng/ml). MCF7/S0.5 express both oestrogen receptor and progesterone receptor.
Research Area Cancer, Drug Discovery & Development
Growth/Phenotype Keywords Adapted to growth in low serum concentrations
Recommended Growing Conditions Phenol-red-free DMEM/F12 medium supplemented with 1% fetal calf serum 2.5 mM Glutamax and 6 ng/ ml insulin,
Notes Passage 408 (AL2542, AL2543)

Grows in low serum
Cellosaurus ID CVCL_1D47

References

There are 20 reference entries for this reagent.

View All References

References: 20 entries

Joshi et al. 2016. Oncotarget. :. PMID: 27528030.

Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.

Europe PMC ID: 27528030

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.

Europe PMC ID: 27252418

Alves et al. 2016. Clin Cancer Res. :. PMID: 27252418.

Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.

Europe PMC ID: 26585578

Thomsen et al. 2015. Breast Cancer Res Treat. :. PMID: 26585578.

Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.

Europe PMC ID: 25625755

Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.

Europe PMC ID: 15748829

Sonne-Hansen et al. 2005. J Steroid Biochem Mol Biol. 93(1):25-34. PMID: 15748829.

Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-34. PMID: 7759159.

Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.

Europe PMC ID: 7759159

Lykkesfeldt et al. 1994. Cancer Res. 54(6):1587-95. PMID: 8137264.

Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.

Europe PMC ID: 8137264

Lykkesfeldt et al. 1989. Mol Cell Endocrinol. 62(2):287-96. PMID: 2744230.

Regulation of the secretion of proteins synthesized by the human breast cancer cell line, MCF-7.

Europe PMC ID: 2744230

Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines.

Europe PMC ID: 3947513

Lykkesfeldt et al. 1986. Br J Cancer. 53(1):29-35. PMID: 3947513.

Briand et al. 1984. Cancer Res. 44(3):1114-9. PMID: 6362856.

Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration.

Europe PMC ID: 6362856


Add a reference

References: 20 entries

Joshi et al. 2016. Oncotarget. :. PMID: 27528030.

Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.

Alves et al. 2016. Clin Cancer Res. :. PMID: 27252418.

Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.

Thomsen et al. 2015. Breast Cancer Res Treat. :. PMID: 26585578.

Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.

Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.

Sonne-Hansen et al. 2005. J Steroid Biochem Mol Biol. 93(1):25-34. PMID: 15748829.

Lykkesfeldt et al. 1995. Int J Cancer. 61(4):529-34. PMID: 7759159.

Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.

Lykkesfeldt et al. 1994. Cancer Res. 54(6):1587-95. PMID: 8137264.

Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.

Lykkesfeldt et al. 1989. Mol Cell Endocrinol. 62(2):287-96. PMID: 2744230.

Regulation of the secretion of proteins synthesized by the human breast cancer cell line, MCF-7.

Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines.

Lykkesfeldt et al. 1986. Br J Cancer. 53(1):29-35. PMID: 3947513.

Briand et al. 1984. Cancer Res. 44(3):1114-9. PMID: 6362856.

Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration.


Add a reference